Literature DB >> 12408547

A cost analysis of the prostaglandin analogs.

Andrew B Mick1, Serafin Gonzalez, Mark T Dunbar, John J McSoley.   

Abstract

BACKGROUND: The efficacy, ease of use, and favorable side effect profile has increased the popularity of the prostaglandin analogs for topical treatment of a variety of glaucoma types. We undertook a cost analysis study of all the prostaglandin analogs.
METHODS: Mean number of drops per bottle, mean drop volume, total bottle volume, percent overfill per bottle, mean national bottle cost, daily cost of therapy, and yearly cost of therapy were calculated for all four of the prostaglandin analogs.
RESULTS: Yearly cost of monocular therapy was $230.68 for latanoprost, $219.37 for travoprost, $211.34 for bimatoprost, and $178.85 for unoprostone. Unoprostone was by far the least expensive of the prostaglandin analogs tested. Bimatoprost, latanoprost, and travoprost were essentially the same price, varying in yearly cost to the patient by less than twenty dollars. Bimatoprost had the most expensive bottle price, unoprostone the least expensive. Bimatoprost also had the largest percentage of overfill from labeled volume. Unoprostone had the most monocular treatment days per bottle.
CONCLUSION: Cost, in addition to efficacy and side affect profile, should be considered when determining which prostaglandin analog to prescribe to glaucoma patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12408547

Source DB:  PubMed          Journal:  Optometry        ISSN: 1558-1527


  7 in total

Review 1.  Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence.

Authors:  Michelle Orme; Annabel Boler
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 2.  The economic implications of glaucoma: a literature review.

Authors:  Jordana K Schmier; Michael T Halpern; Mechelle L Jones
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.

Authors:  Gregory Reardon; Gail F Schwartz; Sameer Kotak
Journal:  BMC Ophthalmol       Date:  2010-03-02       Impact factor: 2.209

4.  Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.

Authors:  John G Walt; Jacob T Wilensky; Richard Fiscella; Tina H Chiang; Angela Guckian
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 5.  Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension.

Authors:  Greg L Plosker; Susan J Keam
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.

Authors:  Lawrence D Goldberg; John Walt
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension.

Authors:  Ronald E P Frenkel; Max Frenkel; Allison Toler
Journal:  BMC Ophthalmol       Date:  2007-09-27       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.